Laura van ‘t Veer, Ph.D.
Leader, Breast Oncology Program, and
Associate Director, Applied Genomics
Helen Diller Family Comprehensive Cancer Center
University of California at San Francisco (UCSF)
Dr. van ‘t Veer is a world renowned Molecular Biologist, former Head of Diagnostic Oncology at the Netherlands Cancer Institute, and inventor of MammaPrintÒ. She is the Leader of the Breast Oncology Program in the Helen Diller Family Comprehensive Cancer Center and a convenor of UCSF’s Precision Medicine Platform. Dr. van ‘t Veer’s research focuses on Personalized Medicine, to advance that patient management is based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. This allows to optimally assign systemic therapy for those patients that are in need of such treatment and to ensure the selection of the therapy that is most effective. Dr. van ‘t Veer’s research shows that molecular diagnostics and microarray genomics technology increasingly impacts patient management. Molecular Genomics contributes to the knowledge of who is at risk for breast cancer, how external factors may influence this risk, whether breast tumors are likely to metastasize or not, and which subtype of tumors will likely respond to what therapy.